Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Feb 21, 2024 11:56am
117 Views
Post# 35891060

RE:At least another year of waiting...

RE:At least another year of waiting...He keeps talking about accretive product acquisition for  the umpteenth time...Sales are up  but not exceeding guidance ,,For sure they are very cautious in everything they say on the advice of theur lawyer.....
Hard to be impressed by anything said during the CC....At least the SP does not appear to be overvalued and any bit of good news could have a positive effect

PWIB123 wrote: I love how Paul on the conference call made it sound like a victory of how well the company has crawled out of the deficit of a hole they got themselves into after making financial and operational mistakes.  It's hard not to be completely pessimistic.  Basically all I took away was that they finally got their spending under control and have flat expectations for the future without something good coming out of oncology.  That, and we'll be waiting until the end of 2024 on TH-1902, so still dead money for longer.


<< Previous
Bullboard Posts
Next >>